Rani Therapeutics

Rani Therapeutics Awarded Great Place to Work for 3 Years in a Row! We are thrilled to announce that Rani Therapeutics has been awarded the Great Place to Work certification for the third year in a row! This is a testament to our commitment to creating a positive and supportive work environment for all of our employees. We believe that our employees are our greatest asset, and we are committed to providing them with the culture, tools and resources they need to be successful. We would like to thank all of our employees for their hard work and dedication. We are proud to have such a talented and passionate team! Go #TeamRani!! #RaniTherapeutics #GreatPlaceToWork #EmployeeRecognition #Culture #RaniPill

“The pharmacokinetic data announced today combined with the previously announced pharmacodynamic data further highlight the RaniPill’s potential to serve as a novel delivery platform for incretin triagonists, a next generation modality for the treatment of obesity,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. Read more below on the new data announced today and how the #RaniPill has the potential to replace painful injections with oral alternatives. #RaniTherapeutics #GLP #obesity #triagonist https://lnkd.in/gAHQP7Fq

🎉 Exciting News from Rani! We are thrilled to announce the promotion of two outstanding team members to Vice President roles within our senior management team! Ali Javadi, Ph.D. VP, Technical Operations With over 15 years of expertise in technical and operational leadership, and 3 years at Rani, Alireza’s expanded role will include: ◾ Leading technical R&D, manufacturing and automation teams Kyle Horlen, DVM VP, Nonclinical Development & Safety Assessment Bringing 15 years of nonclinical experience and 12 years with Rani, Kyle’s responsibilities include: ◾ Overseeing nonclinical efforts, including IND-enabling studies Congratulations to Alireza and Kyle on these well-deserved promotions! We value their leadership and contributions to our success! #Leadership #Promotion #TeamRani #Innovation #RaniPill

Our CBO Kate Flavin McKinley and CFO Svai Sanford have the honor of presenting in a fireside chat this week at the 2024 Cantor Global Healthcare Conference #CantorHCC. We are excited for the opportunity to share more on how our #RaniPill platform has the potential to replace subcutaneous injection and intravenous infusion of biologics and drugs with oral dosing. Tune in on our webcast: https://bit.ly/4ekUsu9

On this #LaborDay weekend, we extend our admiration and support to our dedicated employees and our industry colleagues that work hard every day to serve patients and improve lives. At #RaniTherapeutics our Team is committed to advancing our RaniPill platform to realize our mission to replace subcutaneous injections and intravenous infusion of biologics and drugs with oral dosing. #RaniTherapeutics #RaniPill #LaborDay2024

Today at Rani, we had some fun with Hawaiian Shirt Day! 🎉 Our team wore their best Hawaiian themed shirts to the office, showing off their personality and team spirit. It's great to see everyone getting involved and making the workplace a little more colorful. Check out some of our team’s best looks! 😎 #HawaiianShirtDay #RaniTeam #RaniBingo

Rani Therapeutics Chief Business Officer Kate Flavin McKinley and Chief Financial Officer Svai Sanford will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference to speak on how our RaniPill platform has the potential to replace subcutaneous injection and intravenous infusion of biologics and drugs with oral dosing. Learn more about our oral delivery #RaniPill platform here: https://bit.ly/3L55bJV

We are excited to share our recent publication based on data generated from two surveys as well as a clinical study to evaluate patient and physician preference for oral versus injectable therapies. The majority of respondents surveyed stated they would be willing to convert to an oral alternative over their current parenteral therapy, regardless of drug, disease or dosing frequency. Additionally, the data shows that patients currently taking injections and prescribing physicians strongly prefer oral dosing to parenteral administration of biologics even if dosing frequency with the oral option is increased. Read the publication here to learn more: https://bit.ly/4ccoEp8 You can watch the video abstract of the manuscript here: https://bit.ly/3ylVC8H #OralDelivery #OralBiologics #RaniPill #RaniTherapeutics

Happy 4th of July! Today and every day we have immense gratitude and celebrate our great America – the land of independence, opportunity, and innovation!  ❤️ 🗽 🎆 💙

Today we announced a definitive agreement with ProGen for the co-development and commercialization of RT-114, an oral RaniPill® capsule containing ProGen’s GLP-1/GLP-2 dual agonist, for the treatment of obesity. RT-114 is designed to provide a differentiated oral delivery mechanism with the potential to offer advantages over other weight management candidates in development.  https://lnkd.in/gTM5sxKN #OralDelivery #OralBiologics #RaniPill #RaniTherapeutics #obesity #GLP